McKesson Stock News

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetr...

IRVING, Texas--(BUSINESS WIRE)--McKesson launched an initiative addressing the clinical challenges and administrative burden practices face in the era of biomarker-directed care.

Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in technology stocks and even more from the Magnificent 7, the idea of investing in low-growth dividend stocks loses some appeal.

This medical supplies distributor stock is off a recent high and back in a buy zone. The post This Medical Supplies Distributor Dodges A Tariff Bullet appeared first on Investor's Business Daily.

IRVING, Texas--(BUSINESS WIRE)--Register to attend McKesson ideaShare, a premier community pharmacy annual education and networking event, in Nashville from July 10-13, 2025.

An aging U.S. population is increasing the demand for medication, and this company delivers.

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management servi...

I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue gro...